Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Locally Advanced or Metastatic Urothelial Carcinoma Being Included in the List of Drugs Granted Breakthrough Therapy Designation

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Iza-Bren (EGFR×HER3 Dual Antibody ADC) for Injection for Patients with Locally Advanced or Metastatic Urothelial Carcinoma Being Included in the List of Drugs Granted Breakthrough Therapy Designation

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis